European Heart Journal Advance Access published online on May 25, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi321
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine, Cardiology Division, Johns Hopkins University School of Medicine, Ross 1059, 720 Rutland Avenue, Baltimore, MD 21205, USA
* To whom correspondence should be addressed.
Editorial
Xanthine oxidase inhibitors: an emerging class of drugs for heart failure
Joshua M. Hare, E-mail: jhare{at}mail.jhmi.edu
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. Widimsky, M. Penicka, O. Lang, T. Kozak, Z. Motovska, R. Jirmar, and M. Aschermann Intracoronary transplantation of bone marrow stem cells: background, techniques, and limitations Eur. Heart J. Suppl., December 1, 2006; 8(suppl_H): H16 - H22. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pacher, A. Nivorozhkin, and C. Szabo Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev., March 1, 2006; 58(1): 87 - 114. [Abstract] [Full Text] [PDF] |
||||

